Illumina, Inc. (ILMN)

Illumina is the world’s leading maker of machines and reagents for DNA sequencing — the process of reading the order of letters in a strand of DNA. The company was founded in 1998 just as genomic science was beginning to move from academic labs into mainstream use, and it developed the core technology that has come to dominate the market. Today, Illumina’s sequencers are used in hospitals and diagnostic labs to identify genetic disorders and disease risks, in pharmaceutical companies to screen drug candidates, in agricultural research to breed better crops, in pathogen surveillance to track disease outbreaks, and in fundamental biological research worldwide. The business model is classic recurring revenue: Illumina sells instruments that customers use repeatedly, and charges for the chemical reagents — the enzymes and dyes — that make each run possible. That combination has given the company exceptional profitability and growth.

The company’s dominance in sequencing reflects both superior technology and network effects. Scientists use Illumina machines because the ecosystem of software, databases, and analytical tools built around them is vast. Diagnostic labs and hospitals use them because established protocols and validation suites exist. Sequencing data from research already run on Illumina machines is comparable to new data on Illumina machines, so switching to a competitor means starting those comparison analyses over. That creates stickiness, and stickiness has translated into market share that has remained above seventy percent for years.

Illumina sits in a privileged position between two vast and growing markets: the life sciences and medical diagnostics industries, both of which are spending on genomic analysis because the data is increasingly useful. Pharmaceutical companies use sequencing to understand disease biology and to search for compounds that might work. Clinicians use it to diagnose rare genetic diseases in children, to predict cancer risk, and to inform treatment decisions. Researchers use it to understand human evolution, to catalog the microbiome, to study plant genetics. Each of these applications is still early — the installed base of sequencers is much smaller than the population of diseases, patients, and research projects that could benefit from it — so the addressable market is expanding.

From birth to market dominance

Sequencing technology existed well before Illumina, but the methods were slow, costly, and laborious. A researcher in the late 1990s sequencing a gene typically spent months and tens of thousands of dollars. The Human Genome Project, the international effort to sequence the entire human genome, took over a decade and cost over a billion dollars. The insight behind Illumina’s founding was that optical methods and fluorescent chemistry could speed sequencing enormously. Illumina developed a technique called sequencing-by-synthesis, in which DNA is copied in place on a glass slide, with each base incorporation triggering a flash of fluorescence that a camera records. That approach was far faster and cheaper than alternatives and proved to scale far better as the company invested in manufacturing.

The early 2000s saw Illumina grow from a startup into a significant company by winning over major research institutions. The turning point came as Illumina’s costs fell and its throughput rose. By the early 2010s, sequencing a human genome had gone from a billion-dollar project to something that could be done in days for a few thousand dollars. That cost collapse opened new applications — whole-genome sequencing of patients became economically possible, newborn screening programs could test for genetic disorders, cancer genomics moved from research into the clinic. Illumina rode that wave.

The company went public in 2000 and navigated the dot-com crash. It made several strategic acquisitions, most notably the 2007 purchase of Solexa, which held the sequencing-by-synthesis patents that became the core of Illumina’s product line. In 2014, Illumina acquired Epicentre (molecular biology reagents) and Foundation Medicine (a clinical genomics company), moves that integrated more of the ecosystem around sequencing. Most significantly, in 2018 Illumina acquired GRAIL, a diagnostics company focused on early cancer detection via blood tests, a bet that sequencing would become central to cancer screening and monitoring.

How the business makes money

Illumina generates revenue from two sources: instruments and consumables. Sequencers are expensive machines costing tens of thousands to hundreds of thousands of dollars depending on the model. A research lab or hospital buys one, and then the real economics begin. Every run of the machine requires reagent kits — the chemicals that make sequencing possible. These reagent kits are consumables that must be replenished after each use, and their price is set by Illumina with very high margins because switching costs are steep. Once a customer has bought an Illumina instrument and trained staff on it, moving to a competitor means abandoning that capital investment and retraining.

The installed base of Illumina sequencers worldwide is large and keeps growing. Each installed base customer represents an ongoing stream of consumable sales that persists for years. A typical sequencer might run hundreds or thousands of samples per year, and Illumina captures the margin on each. That combination — high-margin consumables sold repeatedly to a sticky installed base — produces the kind of profitability that investors love. Gross margins on consumables run in the range of seventy to eighty percent, and the business benefits from operating leverage because the incremental cost of producing more reagents is low relative to the selling price.

Illumina also earns revenue from its clinical diagnostics business, including GRAIL, where the company performs tests on patient samples and bills insurance or patients for the results. That business is still growing but remains much smaller than the core sequencing equipment and reagents business.

The competitive landscape and risks

Illumina’s dominance is real but not absolute. Competitors include Pacific Biosciences, Oxford Nanopore, and startups in long-read sequencing that claim to offer advantages over Illumina’s short-read approach. International competitors, particularly in China, have been investing heavily in sequencing technology. Illumina’s lead is likely to persist — the network effects, the quality of the technology, and the size of the installed base are all formidable advantages — but the market is large enough that competitors can grow without displacing Illumina entirely.

The bigger question is whether sequencing adoption will keep accelerating. The cost of sequencing has fallen so far that the limiting factor is no longer price but rather the complexity of analyzing and interpreting the data, the regulatory landscape around genetic testing, and the willingness of hospitals and patients to adopt it. In clinical diagnostics, sequencing is becoming routine for rare disease diagnosis and cancer, but widespread screening applications remain contested. Insurance coverage is still inconsistent, and the legal and ethical questions around genetic testing are unresolved. Those are not technological problems that Illumina can solve alone.

Regulation also looms. Clinical genomics labs must meet quality standards, and regulators worldwide are developing frameworks for what genetic tests can be marketed and how. Strict regulation could slow adoption; light regulation might lead to poor or misleading tests that damage the field’s reputation. Illumina has a stake in both outcomes because uncontrolled testing would hurt long-term trust in the science.

Finally, there is the question of pharmaceutical utility. Illumina’s business has benefited from pharmaceutical companies’ investments in genomic drug discovery and development. A slowdown in drug development spending would ripple through sequencing demand. Similarly, if sequencing proves less useful than hoped for understanding disease and drug response, growth could plateau.

Research and the path forward

Understanding Illumina as an investment requires tracking sequencing adoption — not just in research, but in clinical diagnostics and public health applications. Watch the company’s disclosures on installed base, sequencer unit sales, and the price trends in consumables. Gross margins on consumables are the economic engine, and anything that compresses those margins (price competition, commoditization of reagent kits) would hit profitability hard.

The clinical diagnostics segment, including GRAIL, is central to the long-term story. GRAIL is testing the hypothesis that blood-based sequencing can detect cancers early and improve outcomes. Success would open a massive market; failure would be a significant disappointment. Track enrollment and outcomes in clinical trials, insurance coverage decisions, and any comments from management about adoption timelines.

Competitive threats from long-read sequencing and from international players are worth monitoring. Illumina owns the vast majority of the market today, but market share can shift if competitors gain technical advantages. Finally, watch regulatory developments in clinical genomics — changes to laboratory standards, reimbursement rules, or restrictions on what tests can be marketed would directly affect the company’s growth trajectory and profitability.